Drug delivery tech receives funding

By Nick Taylor

- Last updated on GMT

Related tags: Pharmacology

NovaDel Pharma has secured $2.5m in financing, some of which will be used to further use of its proprietary drug delivery technology.

The funding is the final chunk of the $4m it obtained from the venture capital firm ProQuest Investments, with NovaDel believing it has sufficient money to keep it going through the first half of 2009.

Over this period the company is seeking to continue development of its drug delivery technology, NovaMist. This provides a way to administer therapeutics to the mouth lining, which NovaDel claims offers a range of advantages.

Since NovaMist administers the drug through the highly absorptive buccal lining it quickly enters the bloodstream, ensuring a fast onset of action and reducing the therapeutic dosage that is required.

This route of administration means that the therapeutic avoids being metabolised by the liver, resulting in an increase in bioavailability compared to other delivery routes.

NovaDel also claims that the technology can increase patient compliance, which can in part be attributed to the convenience of not needed to swallow or have water to take the medication.

To date the technology has been used in one commercialised product, NitroMist, which is used for the treatment of angina.

A further commercialisation is a possibility, with NovaDel filing a new drug application (NDA) in September for ZolpiMist, a treatment that uses the delivery technology to administer zolpidem for insomnia sufferers.

The company’s pipeline also contains a treatment for nausea, for which a NDA is expected to be submitted in 2008, and four other formulations at various stages of preclinical and clinical development. In addition the company is developing a lower dose version of ZolpiMist for the treatment of middle-of-the-night awakenings.

All the formulations use the NovaMist technology, which is protected worldwide by 79 patents issued and over 90 that are pending.

Related topics: Ingredients, Delivery technologies

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us


View more